A-Alpha Bio

The latest research insights from A-Alpha Bio’s ML and Data Science Team.

New platform gives researchers access to the quantity and quality of antibody-antigen affinity and structural data required for next-generation protein engineering models.

A-Alpha Bio shares curated content.

Platform users can validate affinity and specificity of computationally designed binder predictions through AlphaSeq.

The company aims to improve human health by unlocking the potential of protein-protein interactions.

A-Alpha Bio leverages synthetic biology and machine learning to measure, understand, and engineer protein-protein interactions

A-Alpha Bio can be contacted through its form or by email.

Measure more protein interactions

Seattle-based A-Alpha Bio raises $22.4 million in Series A2 funding, bringing its total funding to $51 million. Perceptive Xontogeny Ventures leads the round, with support from Madrona and Breakout Ventures.

Jul 2023 · The SaaS NewsNews article

A-Alpha Bio raises $22.4 million in a Series A2 round led by Perceptive Xontogeny Ventures, with support from Madrona and other existing investors. Breakout Ventures joins as a new investor, as the company plans to scale its protein-protein interaction data platforms and accelerate internal pipeline development.

Jul 2023 · PRWebNews article

A-Alpha Bio closes a $20M Series A financing led by Madrona Venture Group to accelerate drug discovery through large-scale measurement of protein-protein interactions. Perceptive Xontogeny Venture Fund and Lux Capital also participate in the round.

Sep 2021 · PRWebNews article

A-Alpha Bio uses technology to analyze millions of protein-protein interactions simultaneously, aiming to speed drug discovery research for pharmaceutical companies. The startup raises a $20 million Series A led by Madrona Venture Group, with Perceptive Xontogeny Venture Fund and Lux Capital also investing.

Sep 2021 · MedCity NewsNews article